EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter evaluation of an enzyme immunoassay (Platelia Aspergillus) for the detection of Aspergillus antigen in serum



Multicenter evaluation of an enzyme immunoassay (Platelia Aspergillus) for the detection of Aspergillus antigen in serum



Mycopathologia 155(3): 129-133



Invasive aspergillosis is a serious problem for immunocompromised patients, especially if neutropenic. The diagnosis of this infection is complicated, since clinical symptoms are often similar to those of other fungal diseases. The chance of detecting the presence of a specific antigen in the serum could confirm the suspected clinical diagnosis and. perhaps, be useful for the follow-up of the patient. The Medical Mycology Committee of the Associazione Microbiologi Clinici Italiani (AMCLI) decided to evaluate in a multicenter prospective study (from I November 1998 to 28 February 1999) the performance of the Platelia Aspergillus Kit (Bio-Rad) for the detection of Aspergillus galactomannan in human serum. The enrolled patients included various groups of immunosuppressed patients (mostly neutropenic). Blood samples were drawn at the time of enrollment. This decision was based upon a clinical diagnosis of probable aspergillosis (antibiotic non-responsive fever for at least 96 hours, cough, hemophthosis and positive chest X-ray). Additional blood samples were drawn on days 3, 6, 9, 12, 15 and 21. Culture and histopathologic examinations were performed according to the individual laboratory workflow. For each patient the laboratory filled a form with all the available clinical information, to create a database on which to evaluate the results of the test. During the study, 187 patients with various kinds of immunosuppression were enrolled. A total of 256 sera were tested: for 117 patients (62.6%) only the basal sample was tested, whereas for the 70 symptomatic patients (37.4%) multiple specimens (range: 1-6) were tested. The results allowed the laboratories to exclude (68.6%) or confirm (31.5%: confirmed and/or probable) the clinical diagnosis of invasive aspergillosis; 4 cases remained undetermined. Based on the results of this study, it seems that the use of this test should be limited to those patients with clinical symptoms of aspergillosis.

(PDF emailed within 1 workday: $29.90)

Accession: 049634434

Download citation: RISBibTeXText

PMID: 12617498



Related references

Multicenter evaluation of an enzyme immunoassay Aspergillus for the detection of Aspergillus antigen in serum. Mycopathologia 155(3): 129-133, 2002

Multicenter evaluation of an enzyme immunoassay (PlateliaReg. Aspergillus) for the detection of Aspergillus antigen in serum. Mycopathologia 155(3): 129-133, 2002

Lack of intra-laboratory reproducibility in using Platelia Aspergillus enzyme immunoassay test for detection of Aspergillus galactomannan antigen. Transplant Infectious Disease 14(1): 107-109, 2012

Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. Clinical and Vaccine Immunology 15(12): 1760-1763, 2008

Aspergillus galactomannan antigen detection with Platelia Aspergillus: Multiple positive antigenemia without Aspergillus infection. Journal de Mycologie Medicale 8(2): 112-113, June, 1998

Improved Standardization of the Bio-Rad Platelia Aspergillus Galactomannan Antigen Sandwich Enzyme Immunoassay Using the DS2 (Dynex) Enzyme-Linked Immunosorbent Assay (ELISA) Processing System. Journal of Clinical Microbiology 53(7): 2072-2078, 2016

Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. Journal of Clinical Microbiology 42(1): 435-438, 2004

Assessment of Platelia Aspergillus enzyme immunoassay for the diagnosis of invasive aspergillosis. Journal of Microbiology, Immunology, and Infection 40(2): 148-153, 2007

Cross-reactivity in the Platelia™ Aspergillus enzyme immunoassay caused by blastomycosis. Medical Mycology 50(4): 396-398, 2012

Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clinical and Vaccine Immunology 14(5): 638-640, 2007

Galactoxylomannan does not exhibit cross-reactivity in the platelia Aspergillus enzyme immunoassay. Clinical and Vaccine Immunology 14(5): 624-627, 2007

Value of Aspergillus antigen with Platelia Aspergillus in respiratory fluid in the diagnosis of invasive Aspergillosis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 387, 2001

Variability in Galactomannan detection by Platelia Aspergillus EIA™ according to the Aspergillus species. Revista do Instituto de Medicina Tropical de Sao Paulo 55(3): -, 2013

Cross-reactivity of Paracoccidioides brasiliensis, Histoplasma capsulatum, and Cryptococcus species in the commercial Platelia Aspergillus enzyme immunoassay. Clinical and Vaccine Immunology 16(1): 132-133, 2008

Cross-reactivity of the PLATELIA CANDIDA antigen detection enzyme immunoassay with fungal antigen extracts. Journal of Clinical Microbiology 41(7): 3395-3398, 2003